This distribution mirrors the general GLP-1 market, where semaglutide dominates prescribing patterns
Based on this, some mechanistic explanations have been proposed for the loss of strong opioid effectiveness in NP conditions, including the release of dynorphin [67], the downregulation of MOR in the spinal cord [76,77] and dorsal root ganglion (DRG) [78,79], the increase in the serotonin level [80], increased methylation of the MOR gene promoter in DRG and/or the stimulation of glutamate receptor [81], the decrease in morphine concentration in the brain [86], etc
This improvement may be attributed to: Weight Loss: As GLP-1 agonists promote weight loss, individuals may find relief from obesity-related sleep issues, such as obstructive sleep apnea (OSA)
Furthermore, aggressive heat lasers can compromise the skin barrier, leading to severe post-treatment dryness and irritation in sensitive, breakout-prone skin
For individuals who struggle with low mood during the winter, the colder months can produce feelings of melancholy and anxiousness